I. Koumenis

Potentiation of murine astrocyte antioxidant defence by bcl‐2: protection in part reflects elevated glutathione levels

R. Giffard, Lijun Xu, Marios C. Papadopoulos, 1998, The European journal of neuroscience.

Overexpression of bcl-xL protects astrocytes from glucose deprivation and is associated with higher glutathione, ferritin, and iron levels.

J. Tilly, R. Giffard, I. Koumenis, 1999, Anesthesiology.

Inhibition of leukotriene synthesis, pharmacokinetics, and tolerability of a novel dietary fatty acid formulation in healthy adult subjects.

F. Chilton, M. Surette, M. Edens, 2003, Clinical therapeutics.

Inhibition of leukotriene biosynthesis by a novel dietary fatty acid formulation in patients with atopic asthma: a randomized, placebo-controlled, parallel-group, prospective trial.

F. Chilton, D. Bowton, M. Surette, 2003, Clinical therapeutics.

Increasing vulnerability of astrocytes to oxidative injury with age despite constant antioxidant defenses

M. Papadopoulos, R. Giffard, I. Koumenis, 1997, Neuroscience.

A double-blind, placebo-controlled trial of ruxolitinib for myelofibrosis.

Jason Gotlib, Moshe Talpaz, J. Dipersio, 2012, The New England journal of medicine.

Modulating pharmacokinetics of an anti-interleukin-8 F(ab')(2) by amine-specific PEGylation with preserved bioactivity.

Z. Shahrokh, L. Deforge, G. Zapata, 2000, International journal of pharmaceutics.

Vulnerability to glucose deprivation injury correlates with glutathione levels in astrocytes

M. Papadopoulos, R. Giffard, L. Dugan, 1997, Brain Research.

Adapting pharmacokinetic properties of a humanized anti-interleukin-8 antibody for therapeutic applications using site-specific pegylation.

L. Presta, B. Snedecor, Z. Shahrokh, 2001, Cytokine.

Results of COMFORT-I, a randomized double-blind phase III trial of JAK 1/2 inhibitor INCB18424 (424) versus placebo (PB) for patients with myelofibrosis (MF).

J. Dipersio, H. Kantarjian, S. Verstovsek, 2011, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

Safety and antitumor activity of recombinant soluble Apo2 ligand.

D. Lawrence, H. Koeppen, Z. Shahrokh, 1999, The Journal of clinical investigation.